Zamtocabtagene Autoleucel Shows High Response Rates in Relapsed/Refractory DLBCL
Findings from the phase 2 DALY II USA trial showed that the 28-day objective response rate was 78% with freshly administered zamtocabtagene autoleucel, exceeding the prespecified efficacy threshold for interim analysis.
Nirav N. Shah, MD
When freshly administered, the dual CD19- and CD20-directed, chimeric antigen receptor (CAR) T-cell therapy zamtocabtagene autoleucel (zamto-cel; MB CART2019.1) showed encouraging safety, including a high response rate with deepening responses over time in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to prespecified interim results from the phase 2 DALY II USA trial (NCT04792489).1
Findings presented at the 2023 Transplantation & Cellular Therapy Meetings showed that the 28-day objective response rate (ORR) per independent radiology review (IRC) was 78% (complete response [CR], 32%; partial response [PR], 46%), exceeding the prespecified efficacy threshold for interim analysis. The best objective response rate was 82% (CR, 46%; PR, 36%).
“DALY-II-USA is the first bispecific anti-CD20/anti-CD19 CAR T trial utilizing fresh infusion with a CAR T-cell product for patients with relapsed/refractory LBCL who received at least 2 lines of treatment,” lead study author Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, said in a presentation of the data.
Although CD19-directed CAR T-cell therapy is approved for the treatment of patients with relapsed/refractory DLBCL, relapse remains an issue. Downregulation of the CD19 receptor or loss of epitope recognition may be one mechanism responsible for resistance. As such, dual-targeted products may help overcome resistance, leading to improved outcomes.
In a first-in-human trial (NCT03019055), investigators demonstrated the feasibility of administering fresh cells with LTG 1497––a construct identical to MB CART2019.1––with a high response rate and remissions lasting over 4 years following infusion.2 Additionally, the phase 1/2 DALY I trial (NCT03870495) showed that the MB CART2019.1 product was well tolerated without severe cytokine release syndrome (CRS) or neurotoxicity and an ORR of 75% and a CR rate of 42% (n = 5/12).3
The single-arm, open-label phase 2 DALY II study was designed to evaluate the efficacy, safety, and pharmacokinetic persistence of zamto-cel in 59 adults with relapsed/refractory DLBCL.
To be eligible for enrollment, patients had to be at least 18 years of age and have an ECOG performance status of 0 or 1, histologically confirmed LBCL, measurable disease confirmed by PET/CT per Lugano 2014 criteria, and received at least 2 prior lines of therapy, including rituximab (Rituxan) and anthracycline-based chemotherapy.
Patients underwent screening on day –45 and leukapheresis on day –14. Patients received lymphodepleting chemotherapy consisting of 30 mg/m2 of fludarabine and 300 mg/m2 of cyclophosphamide on days –5, –4, and –3, or 90 mg/m2 of bendamustine on day -4 and -3. On day 0, patients received zamto-cel at 2.5 x 106 CAR T cells/kg.
“[A] rapid centralized manufacturing process allowed for 14 days ‘vein to vein’ fresh CAR T-cell infusions throughout the United States with lymphodepletion initiated during this process,” Shah said.
The primary end point of the study was the 28-day ORR per IRR. Secondary end points included CR rate, duration of response, best objective response, progression-free survival (PFS), overall survival, safety, cellular kinetics, and cytokine levels.
Of the 36 patients screened, 28 were leukapheresed and 28 received zamto-cel. Twenty-seven patients received the fresh product, but 5 were nonconforming and 1 was cryopreserved, leaving 22 patients evaluable for the analysis.
Regarding baseline characteristics in the evaluable population, the median age was 59 years (range, 37-75) and most patients were male (60%) with an ECOG performance status of 1 (77%). The population was representative of “advanced disease,” Shah said, with an International Prognostic Index of 3 to 5 (68%), elevated lactate dehydrogenase (68%), at least 2 extranodal sites (55%), and receipt of 2 prior lines of therapy (72%).
Patient characteristics were similar in all treated patients (n = 28), Shah noted. Regarding histology, DLBCL (46%) and germinal center B-cell like (35%) were the most common, followed by high-grade B-cell lymphoma (11%), primary mediastinal large B-cell lymphoma (4%), and transformed lymphoma (4%).
Notably, prior treatment for the evaluable population included anti-CD19 antibodies (13%) and polatuzumab vedotin-piiq (Polivy; 9%), “representing contemporary prior treatment algorithms including agents not available in earlier pivotal trials,” Shah said.
At a median follow-up of 10.3 months, 8 deaths occurred, owing to DLBCL (n = 6) and COVID-19 (n = 2).
Additional findings indicated that the 6-month PFS rate in the all-treated and evaluable populations were similar at 61% and 64%, respectively.
“Durable responses were observed in the majority of treated patients, with durable persistence of CD19 and CD20 CAR T cells,” Shah said.
Among the patients with disease progression (n = 14), 2 patients experienced CD20 loss and 1 experienced both CD19 and CD20 loss.
Regarding safety among all treated patients, CRS occurred in 61% of patients (grade 1, 43%; grade 2, 18%; grade 3, 0%) and immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 22% of patients (grade 1, 4%; grade 2, 11%; grade 3, 7%). Management strategies consisted of steroids (21%), tocilizumab (18%), and anakinra (7%).
“Zamto-cel was well tolerated with only 2 [instances of] reversible grade 3 ICANS and no grade 3/4 CRS,” Shah said.
Early onset of cytopenia within the first 28 days after infusion occurred in 85% of patients (grade 3, 21%; grade 4, 64%). Late onset of cytopenia after day 28 occurred in 18% of patients (grade 3, 14%; grade 4, 4%).
Most manifestations of CRS and ICANS were low grade compared with hematologic, autoimmune, and infection-related events.
Editor’s note: Dr Shah reported serving as an advisor for Legend, Epizyme, TG-therapeutics, Kite Pharma, Novartis, LOXO-Lilly Oncology, Janssen, BMS-Juno, and Seattle Genetics; receiving research funding from Miltenyi Biotec and LOXO-Lilly Oncology; serving as a consultant for Miltenyi Biotec, Lilly Oncology, and Incyte; and being a member/founder of Tundra Therapeutics.
References:
Shah NN, Maziarz RT, Jacobsen C, et al. Interim analysis of a phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T-cell therapy – zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL. Presented at: 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 15-19, 2023; Orlando, FL. Abstract 16.
Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569-1575. doi:10.1038/s41591-020-1081-3
Borchmann P, Lohneis A, Gödel P, et al. Phase I trial of MB-CART2019.1 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: 2-year follow-up report. Presented at: 2022 EHA Congress; June 9-12, 2022; Vienna, Austria. Poster 1184.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
